Trial · NCT06920511
Cognitive Rehabilitation With Virtual Reality in Parkinson Disease
NCT06920511, Not applicable, Completed, Fondazione Don Carlo Gnocchi ETS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cognitive Rehabilitation With Virtual Reality in Parkinson Disease. Trials, record NCT06920511. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06920511
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cognitive Rehabilitation With Virtual Reality in Parkinson Disease
- NCT number
- NCT06920511
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 10 participants, actual
- Lead sponsor
- Fondazione Don Carlo Gnocchi ETS
- Conditions
- Parkinson Desease, Mild Cognitive Impairment (MCI)
- Interventions
- Cognitve rehabilitation with virtual reality and robotic arm
- First posted
- 2025-04-09
- Last updated
- 2026-09-11
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | System Usability Scale (SUS) - Patient Reported Outcome | Week 4 (post-treatment, T1) | Assessment of system usability using the 10-item SUS scale. Scores range from 0 to 100; higher scores indicate better usability. |
| Primary | eHealth Usability Benchmarking Instrument (HUBBI) | Week 4 (post-treatment, T1) | Assessment of system usability using the HUBBI questionnaire. Items rated on a 7-point scale; higher scores indicate better usability. |
| Primary | User Experience Questionnaire - Short Version (UEQ-S) | Week 4 (post-treatment, T1) | Evaluation of pragmatic and hedonic user experience with the UEQ-S. Each item rated from -3 to +3; higher scores indicate more positive experience. |
| Primary | Technology Acceptance Model (TAM) and UTAUT Scores | Week 4 (post-treatment, T1) | Evaluation of perceived usefulness and ease of use via TAM and UTAUT scales. Items rated on 5-point Likert scales. |
| Primary | NASA Task Load Index (NASA-TLX) | Week 4 (post-treatment, T1) | Evaluation of cognitive workload using the NASA-TLX scale. Scores range from 0 to 100; higher scores indicate higher workload. |
| Secondary | Session Attendance and Treatment Adherence | Weeks 1-4 | Evaluation of the acceptance of the PRoBio platform by patients and clinicians, based on session attendance, treatment adherence, and system usability for operators. Additionally, the ability of PRoBio to collect biomechanical and psychophysiological data during treatment will be assessed. These include response accuracy and reaction times (collected by VRRS), movement amplitude and velocity (via RGB-D camera), and physiological indicators (heart rate, respiratory rate, and skin conductance) recorded through wearable sensors. These data will be used offline to customize the rehabilitation sessions. |
| Secondary | Response Accuracy in Cognitive Tasks (VRRS Software) | Weeks 1-4 | Accuracy rate in exercises performed during each session, as recorded by VRRS. |
| Secondary | Reaction Times in Cognitive Tasks (VRRS Software) | Weeks 1-4 | Mean reaction times (ms) recorded during cognitive tasks using the PRoBio platform. |
| Secondary | Movement Amplitude (RGB-D Camera Analysis) | Weeks 1-4 | Mean amplitude of upper limb movements captured via RGB-D camera. |
| Secondary | Movement Velocity (RGB-D Camera Analysis) | Weeks 1-4 | Mean velocity of arm movements during tasks, as measured by RGB-D camera. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Other outcome | ConductCognition |
| Trail Making Test A | Other outcome | ConductCognition |
| Trail Making Test B | Other outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06920511
GET https://conductscience.org/api/trials/v1/NCT06920511/registered